RAD001 – Anti-Cancer Therapy

 

Key Data:

Drug (Brand/Generic)
RAD001 (everolimus)
Company/Licensee
Novartis
Therapy Class
Anti-neoplastic agent
Product Description
mTOR inhibitor
Current Indication
Renal cell carcinoma
Market Sector
Oncology
Development Status
Phase III

Return to Project



Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area


RSS What is RSS
For every phase of your drug development